Company / PP&E (Net)
Praxis Precision Medicines, Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$147.0K
FY2025
5-year range
$147.0K / $1.2M
FY2021-FY2025
Trend
-36.1%
vs FY2024
Sector context
#186 of 193
Health Care
What the data says
Among 193 Health Care companies, Praxis Precision Medicines, Inc. is in the bottom 4% for pp&e (net). PP&E (Net) has declined for 4 consecutive years, from $1M in FY2021 to $147,000 in FY2025.
Based on SEC 10-K filings.
$147,000 in FY2025 with a 5-year CAGR of +12.4%.
Declined from $588,000 to $147,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -46.7%
- 5-Year CAGR
- +12.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 193This company $147.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- Praxis Precision Medicines, Inc.'s pp&e (net) has declined for 4 consecutive years.
- 5-year CAGR of +12.4%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 36.1% year-over-year.
- Ranks #186 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 4.48 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $147.0K | -36.1% |
| FY2024 | $230.0K | -60.9% |
| FY2023 | $588.0K | -39.4% |
| FY2022 | $971.0K | -20.0% |
| FY2021 | $1.2M | +1379.3% |
| FY2020 | $82.0K | -35.9% |
| FY2019 | $128.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026